- 2008 (0)
- 2009 (4) Apply 2009 filter
- 2010 (5) Apply 2010 filter
- 2011 (1) Apply 2011 filter
- 2012 (0)
- 2013 (1) Apply 2013 filter
- 2014 (3) Apply 2014 filter
- 2015 (7) Apply 2015 filter
- 2016 (4) Apply 2016 filter
- 2017 (7) Apply 2017 filter
- 2018 (2) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (1) Apply 2021 filter
- (-) Remove Development Finance & Policy filter Development Finance & Policy
- Aid & Other Development Finance (18) Apply Aid & Other Development Finance filter
- Global & Regional Public Goods (8) Apply Global & Regional Public Goods filter
- Monitoring & Evaluation (2) Apply Monitoring & Evaluation filter
- Political Economy & Governance (15) Apply Political Economy & Governance filter
- Household Well-Being & Equity (53) Apply Household Well-Being & Equity filter
- Education & Training (8) Apply Education & Training filter
- Food Security & Nutrition (23) Apply Food Security & Nutrition filter
- Gender (34) Apply Gender filter
- Health (19) Apply Health filter
- Labor & Time Use (20) Apply Labor & Time Use filter
- Poverty (13) Apply Poverty filter
- Risk, Preferences, & Decision-Making (10) Apply Risk, Preferences, & Decision-Making filter
- Sustainable Agriculture & Rural Livelihoods (146) Apply Sustainable Agriculture & Rural Livelihoods filter
- Agricultural Inputs & Farm Management (71) Apply Agricultural Inputs & Farm Management filter
- Agricultural Productivity, Yield, & Constraints (59) Apply Agricultural Productivity, Yield, & Constraints filter
- Environment & Climate Change (26) Apply Environment & Climate Change filter
- Finance & Investment (11) Apply Finance & Investment filter
- Market & Value Chain Analysis (79) Apply Market & Value Chain Analysis filter
- Technology (36) Apply Technology filter
Types of Research
- East Africa Region and Selected Countries (2) Apply East Africa Region and Selected Countries filter
- Global (16) Apply Global filter
- South Asia Region and Selected Countries (3) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (1) Apply Southern Africa Region and Selected Countries filter
- Sub-Saharan Africa (9) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (2) Apply West Africa Region and Selected Countries filter
- ASTI (4) Apply ASTI filter
- FAOSTAT (3) Apply FAOSTAT filter
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (4) Apply Other Datasets filter
In this dataset, we compile current project data from three major international financial institutions (or IFIs) - the World Bank, African Development Bank, and the International Fund for Agricultural Development - to understand
- how much countries are borrowing from each institution. and
- how much of that funding is devoted to small scale producer agriculture.
We begin by gathering publicly accessible data through downloads and webscraping Python and R scripts. These data are then imported into the statistical software program, Stata, for cleaning and export to Excel for analysis. This dataset contains rich information about current projects (active, in implementation, or recently approved), such as project title, project description, borrowing ministry, commitment amount, and sector. We then code relevant projects into two categories: On Farm (projects pertaining directly to small scale producer agriculture) and Rural/Agricultural Economies (inclusive of On Farm, but broader to include projects that impact community livelihoods and wellbeing). Finally, we annualize and aggregate these coded projects by IFI and then by country for analysis. Bilateral funding, government expenditures on agriculture, and development indicators are also included as supporting data to add context to a country's progress towards agricultural transformation.
The primary utility of this dataset is having all projects collected in a single spreadsheet where it is possible to search by key terms (e.g. commodity, market, financial, value chain) for lending by IFI and country, and to get some level of project detail. We have categorized projects by lending category (e.g. irrigation, livestock, agricultural development, research/extention/training) to aggregate across IFI so that the total funding for any country is easier to find. For example, Ethiopia and Nigeria receive the most total lending from these IFIs (though not on a per capita basis), with each country receiving more than $3 billion per year on average. Ethiopia receives the most lending devoted to On Farm projects, roughly $585 million per year. Overall, these data provide a snapshot of the magnitude and direction of these IFI's lending over the past several years to sub-Saharan Africa.
Figone, K., Porton, A., Kiel, S., Hariri, B., Kaminsky, M., Alia, D., Anderson, C.L., and Trindade, F. (2021). Summary of Three International Financial Institution (IFI) Investments in Sub-Saharan Africa. EPAR Technical Report #411. Evans School of Public Policy & Governance, University of Washington. Retrieved <Day Month Year> from https://epar.evans.uw.edu/research/tracking-investment-landscape-summary-three-international-financial-institutions-ifis
Many low- and middle-income countries remain challenged by a financial infrastructure gap, evidenced by very low numbers of bank branches and automated teller machines (ATMs) (e.g., 2.9 branches per 100,000 people in Ethiopia versus 13.5 in India and 32.9 in the United States (U.S.) and 0.5 ATMs per 100,000 people in Ethiopia versus 19.7 in India and 173 in the U.S.) (The World Bank 2015a; 2015b). Furthermore, only an estimated 62 percent of adults globally have a banking account through a formal financial institution, leaving over 2 billion adults unbanked (Demirgüç–Kunt et al., 2015). While conventional banks have struggled to extend their networks into low-income and rural communities, digital financial services (DFS) have the potential to extend financial opportunities to these groups (Radcliffe & Voorhies, 2012). In order to utilize DFS however, users must convert physical cash to electronic money which requires access to cash-in, cash-out (CICO) networks—physical access points including bank branches but also including “branchless banking" access points such as ATMs, point-of-sale (POS) terminals, agents, and cash merchants. As mobile money and branchless banking expand, countries are developing new regulations to govern their operations (Lyman, Ivatury, & Staschen, 2006; Lyman, Pickens, & Porteous, 2008; Ivatury & Mas, 2008), including regulations targeting aspects of the different CICO interfaces.
EPAR's work on CICO networks consists of five components. First, we summarize types of recent mobile money and branchless banking regulations related to CICO networks and review available evidence on the impacts these regulations may have on markets and consumers. In addition to this technical report we developed a short addendum (EPAR 355a) which includes a description of findings on patterns around CICO regulations over time. Another addendum (EPAR 355b) summarizes trends in exclusivity regulations including overall trends, country-specific approaches to exclusivity, and a table showing how available data on DFS adoption from FII and GSMA might relate to changes in exclusivity policies over time. A third addendum (EPAR 355c) explores trends in CICO network expansion with a focus on policies seeking to improve access among more remote or under-served populations. Lastly, we developed a database of CICO regulations, including a regulatory decision options table which outlines the key decisions that countries can make to regulate CICOs and a timeline of when specific regulations related to CICOs were introduced in eight focus countries, Bangladesh, India, Indonesia, Kenya, Nigeria, Pakistan, Tanzania, and Uganda.
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Donor countries and multilateral organizations may pursue multiple goals with foreign aid, including supporting low-income country development for strategic/security purposes (national security, regional political stability) and for short-and long-term economic interests (market development and access, local and regional market stability). While the literature on the effectiveness of aid in supporting progress on different indicators of country development is inconclusive, donors are interested in evidence that aid funding is not permanent but rather contributes to a process by which recipient countries develop to a point that they are economically self-sufficient. In this report, we review the literature on measures of country self-sufficiency and descriptive evidence from illustrative case studies to explore conditions associated with transitions toward self-sufficiency in certain contexts.
Cash transfer programs are interventions that directly provide cash to target specific populations with the aim of reducing poverty and supporting a variety of development outcomes. Low- and middle-income countries have increasingly adopted cash transfer programs as central elements of their poverty reduction and social protection strategies. Bastagli et al. (2016) report that around 130 low- and middle-income countries have at least one UCT program, and 63 countries have at least one CCT program (up from 27 countries in 2008). Through a comprehensive review of literature, this report primarily considers the evidence of the long-term impacts of cash transfer programs in low- and lower middle-income countries. A review of 54 reviews that aggregate and summarize findings from multiple studies of cash transfer programs reveals largely positive evidence on long-term outcomes related to general health, reproductive health, nutrition, labor markets, poverty, and gender and intra-household dynamics, though findings vary by context and in many cases overall conclusions on the long-term impacts of cash transfers are mixed. In addition, evidence on long-term impacts for many outcome measures is limited, and few studies explicitly aim to measure long-term impacts distinctly from immediate or short-term impacts of cash transfers.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.